Literature DB >> 32413420

Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: A combined analysis of phase III randomized controlled trials.

Somedeb Ball1, Sriman Swarup2, Anita Sultan2, Kyaw Zin Thein2.   

Abstract

Entities:  

Keywords:  CDK 4/6 inhibitor; Meta-analysis; QT prolongation; Treatment discontinuation

Year:  2020        PMID： 32413420     DOI： 10.1016/j.hemonc.2020.03.001

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


× No keyword cloud information.
  4 in total

1.  Myocardial dysfunction caused by abemaciclib: a case report.

Authors:  Takuya Oyakawa; Lina Inagaki; Zhensheng Hua; Aya Ebihara; Toshimi Takano; Shinji Ohno; Taro Shiga
Journal:  Int Cancer Conf J       Date:  2021-07-17

Review 2.  Cardio-oncology: Implications for Clinical Practice for Women.

Authors:  Seyed Ebrahim Kassaian; Bhumika Gandhi; Ana Barac
Journal:  Curr Cardiol Rep       Date:  2022-09-16       Impact factor: 3.955

3.  Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.

Authors:  Kathleen Beusterien; Martine C Maculaitis; Bernadette Hallissey; Michael M Gaschler; Mary Lou Smith; Ernest H Law
Journal:  Patient Prefer Adherence       Date:  2021-03-18       Impact factor: 2.711

4.  Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.

Authors:  Jutta Bergler-Klein; Peter P Rainer; Markus Wallner; Marc-Michael Zaruba; Jakob Dörler; Armin Böhmer; Tamara Buchacher; Maria Frey; Christopher Adlbrecht; Rupert Bartsch; Mariann Gyöngyösi; Ursula-Maria Fürst
Journal:  Wien Klin Wochenschr       Date:  2022-05-04       Impact factor: 2.275
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.